Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,369 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Solid Tumors Clear all
Completed Phase 1 Interventional

Phase I Trial of ZIO-101 in Patients With Solid Tumors

NCT00509782
View directory record Official record
Conditions
Solid Tumors
Interventions
ZIO-101
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NCT04068896
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
Interventions
NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

NCT05018273
View directory record Official record
Conditions
Solid Tumors, Adult
Interventions
VB10.NEO
Biological
Lead sponsor
Nykode Therapeutics ASA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
San Francisco, California • New Haven, Connecticut • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Jun 7, 2026, 4:27 AM EDT
Terminated Phase 1 Interventional Results available

PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment

NCT01581541
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
PU-H71
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Jun 7, 2026, 4:27 AM EDT
Not yet recruiting Phase 1 Interventional

NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies

NCT07563829
View directory record Official record
Conditions
Metastatic Malignant Neoplasm
Interventions
NPX372
Drug
Lead sponsor
NextPoint Therapeutics, Inc.
Industry
Eligibility
19 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
La Jolla, California • Baltimore, Maryland • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

NCT00877474
View directory record Official record
Conditions
ADVANCED SOLID TUMORS
Interventions
PM01183
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Jun 7, 2026, 4:27 AM EDT
Active, not recruiting Phase 2 Interventional

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

NCT03212274
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
51
States / cities
Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jun 7, 2026, 4:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of TTX-MC138 in Subjects With Advanced Solid Tumors

NCT06260774
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
TTX-MC138
Drug
Lead sponsor
TransCode Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Dallas, Texas • Houston, Texas • West Valley City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jun 7, 2026, 4:27 AM EDT
Terminated Phase 1 Interventional

First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors

NCT01110083
View directory record Official record
Conditions
Solid Tumors
Interventions
EMD 1204831
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Jun 7, 2026, 4:27 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer

NCT01628029
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Sleep Disorder
Interventions
Counseling, Methylphenidate Hydrochloride, Phototherapy, Placebo Administration, Quality-of-Life Assessment, Sham Intervention, Therapeutic Melatonin
Other · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 7, 2026, 4:27 AM EDT
Not listed Phase 1 Interventional

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

NCT02637531
View directory record Official record
Conditions
Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
Interventions
IPI-549 (eganelisib), Nivolumab
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
11
States / cities
San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT03260322
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ASP8374, Pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jun 7, 2026, 4:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

NCT05438329
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
DB-1305/BNT325, Pembrolizumab, BNT327
Drug · Combination Product
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
42
States / cities
Bullhead City, Arizona • Cerritos, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 7, 2026, 4:27 AM EDT
Recruiting Early Phase 1 Interventional

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

NCT06700070
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Interventions
PBA-0111
Drug
Lead sponsor
Pure Biologics S.A.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Oral PX-866

NCT00726583
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
PX-866
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Safety Study of FP-1039 To Treat Cancer

NCT00687505
View directory record Official record
Conditions
Advanced Cancer
Interventions
FP-1039
Drug
Lead sponsor
Five Prime Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Detroit, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Jun 7, 2026, 4:27 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

NCT05678205
View directory record Official record
Conditions
Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions
AB-201, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Artiva Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

NCT03052205
View directory record Official record
Conditions
Refractory Solid Tumors, Melanoma
Interventions
IMO-2125
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer

NCT04474470
View directory record Official record
Conditions
Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma, Metastatic Solid Tumor, Recurrent Solid Tumor, Head and Neck Cancer
Interventions
NT219, NT219 and ERBITUX® - Dose Escalation, NT219 and ERBITUX® - Expansion
Drug
Lead sponsor
TyrNovo Ltd.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Encinitas, California • Los Angeles, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 7, 2026, 4:27 AM EDT
Recruiting Phase 1 Interventional

A Study of PHST001 in Advanced Solid Tumors

NCT06840886
View directory record Official record
Conditions
Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor
Interventions
PHST001, Chemotherapy per Standard of Care
Biological · Drug
Lead sponsor
Pheast Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

A Study of ZL-1211 in Patients With Advanced Solid Tumor

NCT05065710
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
ZL-1211
Drug
Lead sponsor
Zai Biopharmaceutical (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Scottsdale, Arizona • Lynwood, California • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Jun 7, 2026, 4:27 AM EDT
Terminated Phase 1 Interventional

7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors

NCT00012194
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
7-hydroxystaurosporine, cisplatin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Jun 7, 2026, 4:27 AM EDT
Terminated Phase 1Phase 2 Interventional

OMO-1 in Solid Malignancies

NCT03138083
View directory record Official record
Conditions
Neoplasms
Interventions
OMO-1
Drug
Lead sponsor
Octimet Oncology N.V.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Jun 7, 2026, 4:27 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06031441
View directory record Official record
Conditions
Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
Interventions
RO7566802, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • New Haven, Connecticut • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 7, 2026, 4:27 AM EDT